Chlamydia pneumoniae (TWAR)

CC Kuo, LA Jackson, LA Campbell… - Clinical microbiology …, 1995 - Am Soc Microbiol
Chlamydia pneumoniae (TWAR) is a recently recognized third species of the genus Chlamydia
that causes acute respiratory disease. It is distinct from the other two chlamydial species …

[HTML][HTML] An mRNA vaccine against SARS-CoV-2—preliminary report

LA Jackson, EJ Anderson, NG Rouphael… - New England journal …, 2020 - Mass Medical Soc
Background The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged
in late 2019 and spread globally, prompting an international effort to accelerate development …

Mortality benefits of influenza vaccination in elderly people: an ongoing controversy

…, RJ Taylor, C Viboud, MA Miller, LA Jackson - The Lancet infectious …, 2007 - thelancet.com
Influenza vaccination policy in most high-income countries attempts to reduce the mortality
burden of influenza by targeting people aged at least 65 years for vaccination. However, the …

Standardizing Chlamydia pneumoniae Assays: Recommendations from the Centers for Disease Control and Prevention (USA) and the Laboratory Centre for Disease …

…, MR Hammerschlag, LA Jackson… - Clinical Infectious …, 2001 - academic.oup.com
Chlamydia pneumoniae has been associated with atherosclerosis and several other chronic
diseases, but reports from different laboratories are highly variable and “gold standards” …

[HTML][HTML] Homologous and heterologous Covid-19 booster vaccinations

…, KE Lyke, ME Deming, LA Jackson… - … England Journal of …, 2022 - Mass Medical Soc
Background Although the three vaccines against coronavirus disease 2019 (Covid-19) that
have received emergency use authorization in the United States are highly effective, …

[HTML][HTML] Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase

…, TB Campbell, J Clark, LA Jackson… - … England Journal of …, 2021 - Mass Medical Soc
Background At interim analysis in a phase 3, observer-blinded, placebo-controlled clinical
trial, the mRNA-1273 vaccine showed 94.1% efficacy in preventing coronavirus disease 2019 …

[HTML][HTML] Antibody persistence through 6 months after the second dose of mRNA-1273 vaccine for Covid-19

…, CJ Luke, JH Beigel, LA Jackson… - … England Journal of …, 2021 - Mass Medical Soc
Persistence of Antibody after mRNA-1273 Vaccination A total of 33 participants who received
both doses of the Moderna mRNA-1273 vaccine against SARS-CoV-2 had blood drawn …

Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants

…, M Dunstan, R Erolin, J ffitch, C Fields, LA Jackson… - Science, 2021 - science.org
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mutations may diminish
vaccine-induced protective immune responses, particularly as antibody titers wane over time. …

[HTML][HTML] Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults

…, NG Rouphael, AT Widge, LA Jackson… - … England Journal of …, 2020 - Mass Medical Soc
Background Testing of vaccine candidates to prevent infection with severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) in an older population is important, since increased …

[HTML][HTML] Durability of responses after SARS-CoV-2 mRNA-1273 vaccination

AT Widge, NG Rouphael, LA Jackson… - … England Journal of …, 2021 - Mass Medical Soc
Immunogenicity and the mRNA-1273 SARS-CoV-2 Vaccine Thirty-four adults received two
100-μg injections of the mRNA-1273 SARS-CoV-2 vaccine, and serum anti–spike protein …